Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04 Jan 24, 2022
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating Officer Dec 8, 2021
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer Nov 29, 2021
REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments Nov 17, 2021
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options Nov 10, 2021
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments Nov 9, 2021
Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain Oct 21, 2021
